Teva Discontinues Emrusolmin MSA Study
The Phase 2 TOPAS-MSA trial was halted after an interim analysis showed a low probability of meeting its primary efficacy endpoint.
Updated on Nov. 2, 2026 in Alzheimer’s
Teva will discontinue the Phase 2 TOPAS-MSA study evaluating emrusolmin in adults with multiple system atrophy, following a recommendation from an independent data monitoring committee. The interim futility analysis met its predefined criterion, and no safety concerns were identified.
Why it matters
The decision ends a clinical program for a rare, progressive neurodegenerative disease with no approved disease-modifying treatments in the United States. Findings from the comprehensive analysis of the trial data are expected to inform future research into MSA.
The decision rests on an interim futility analysis that found a low probability of meeting the primary efficacy endpoint if the study continued, against a planned enrollment of about 350 participants. The final outcome of the comprehensive data analysis remains unknown.
The players
Teva Pharmaceutical Industries
Teva is a global pharmaceutical company headquartered in Parsippany, New Jersey, and is the sponsor of the emrusolmin development program.
MODAG GmbH
MODAG GmbH is a German biopharmaceutical company that is developing emrusolmin in partnership with Teva.
U.S. Food and Drug Administration
The FDA is the U.S. federal agency responsible for regulating drugs, and it granted Orphan Drug and Fast Track designations to emrusolmin for MSA.
The details
Teva will work with TOPAS-MSA study investigators to ensure protocols are followed during discontinuation. Emrusolmin is being developed in partnership with MODAG GmbH, and the drug holds FDA Orphan Drug designation for MSA granted in 2022 and Fast Track designation granted in September 2025.
Timeline
November 2, 2026: Teva announced the discontinuation of the TOPAS-MSA study.
November 3, 2026: Teva will hold its third-quarter 2026 earnings call at 8:00 a.m. ET.
Health Landscape
The discontinuation of emrusolmin illustrates the high failure risk in developing treatments under the FDA Orphan Drug designation program, which offers development incentives for rare diseases. MSA remains a condition with limited therapeutic options, and the trial outcome adds to the challenges facing neurodegenerative drug development.
For people living with multiple system atrophy in the United States, the discontinuation means emrusolmin will not become an available treatment option through this trial. Patients and caregivers should consult their neurologists about current management options and any clinical trials still enrolling.
The takeaway
Stopping a late-stage program after an interim analysis can protect patients and resources from a trial unlikely to succeed. Readers following rare neurological conditions should watch for the full TOPAS-MSA findings when they are shared.
What happens next
Teva will hold its third-quarter 2026 earnings call on November 3, 2026, at 8:00 a.m. ET, and a comprehensive analysis of TOPAS-MSA data will follow with plans to share findings with the scientific community.
Further reading
Explore more coverage in the Alzheimer’s section for context on neurodegenerative disease research.
More information
Access the Teva Q3 2026 earnings call webcast on Teva's investor relations site.
